Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 28 October, 2008

Summit Corporation PLC

Directorate change

Summit Corporation plc
("Summit plc" or "the Company")

Oxford, UK, 28 October 2008 -  Summit Corporation plc (AIM: SUMM),  a
leading  UK  biotechnology  company,  is  pleased  to  announce   the
appointment of  Mr Tony  Weir (age  48) as  the new  Chief  Financial
Officer and member  of the  Board of  Directors of  the Company  with
effect from 17 November 2008.

Mr Weir will join  Summit plc from Vernalis  plc (LSE: VER) where  he
held the position of  Chief Financial Officer  for almost ten  years.
During  that  time,  he  guided  the  company  through  a  range   of
transactions, including M&A, licensing deals and raising of  finance.
 He is a Fellow  of the Institute of  Chartered Accountants, holds  a
degree in Mathematics  from the University  of Oxford and  is also  a
non-executive director of Biocompatibles International plc.

Barry Price, PhD, Chairman  of Summit, commented:  "On behalf of  the
Board I would like  to welcome Tony to  Summit.  We are delighted  to
have attracted someone  of his  calibre who  will bring  considerable
financial experience  as  well as  a  deep understanding  of  the  UK
biotechnology sector.  These  qualities will be  of great  importance
for Summit in meeting the future challenges we face in continuing  to
build a successful business."

There  is  no  further  information  required  to  be  disclosed   in
accordance with  Schedule  2, paragraph  (g)  of the  AIM  Rules  for

                              - ENDS -
For more information, please contact:
Summit plc
Steven Lee, PhD, Chief Executive Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951; +44 (0)7825 313476
Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible / Emma Palmer Foster
Tel: +44 (0)207 638 9571
Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc  is  a  leading  UK biotechnology  company  with  a  broad
preclinical  and  clinical  pipeline,  two  world-leading  technology
platforms and  an  innovative  business model  that  is  expected  to
generate sustainable value for investors.
Summit is  developing  multiple  drug programmes  that  target  unmet
medical  needs  from   which  it   intends  to   generate  value   by
out-licensing attractive  late preclinical  or early  clinical  stage
programmes in  return for  upfront, milestone  and royalty  payments.
Summit uses  its  scientific  expertise to  target  orphan  diseases,
neuro-disorders and infectious  diseases. Summit has  signed a  major
licensing agreement with BioMarin in Duchenne muscular dystrophy  and
has co-development  agreements  with  Evolva  (infectious  diseases),
Orient  Pharma  (sialorrhoea)  and   the  Lilly  TB  Drug   Discovery
Initiative (tuberculosis)
Underpinning Summit's  drug pipeline  are two  innovative  technology
platforms:  carbohydrate  chemistry  and  zebrafish  biology.   These
platforms support existing programmes and also will be the source  of
future  programmes  to  replenish  Summit's  drug  pipeline.    These
platform technologies also form the basis of the Company's profitable
service business.
The company listed on the alternative investment market (AIM) of  the
London Stock  Exchange  in  October 2004  -  symbol:  SUMM.   Further
information about the company is available at


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.